Host endosomal entry / trafficking
MoreNasal & Oral Sprays / Rinses
MoreHost targets and pathways
MoreInflammatory and immune modulation
MoreOxidative stress and cytoprotection
MoreReplication inhibition (target unresolved)
MorePleiotropic modulation
MoreAttachment / entry inhibition
MoreNutrients and microbiome support
MoreIL-6 / IL-6R blockade
MorePhysical and extracorporeal interventions
MoreNatural products and extracts
MoreUnconfirmed antiviral rationale
MoreLifestyle, behaviors, and exposure prevention
MoreOther complication management
MoreHost pyrimidine synthesis
MoreDirect viral inactivation
MoreEndothelial / vascular protection
MoreDirect respiratory tract treatments
MoreOther antibodies, proteins, peptides, cells, and RNA therapies
MoreSecondary infection and coinfection management
More
95 patient zansecimab late treatment RCT: 36% higher mortality (p=0.58) and 70% higher combined mortality/intubation (p=0.28).
RCT 95 hospitalized patients with COVID-19 pneumonia showing no significant differences with zansecimab (LY3127804, anti-Angiopoietin-2 antibody).
Jan 2022, Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, https://journals.sagepub.com/doi/10.1177/11795484221119316, https://c19p.org/jones2